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Introduction {#sec007}
============

Advanced glycation end products (AGEs) are cross-linking compounds that play a role in the pathogenesis of aging, diabetic microvascular complications, and cardiovascular disease (CVD). Glycation and oxidation of amino groups on proteins results in AGE formation through a series of nonenzymatic reactions termed the Maillard reaction. AGEs may also be generated more rapidly by reactions with α-dicarbonyls that are produced during oxidative stress \[[@pmed.1003163.ref001],[@pmed.1003163.ref002]\]. Tissue accumulation of AGEs has therefore been proposed as a marker of cumulative 'metabolic stress'. Exogenous AGEs from food (particularly food cooked at high temperatures) \[[@pmed.1003163.ref003]\] and smoking \[[@pmed.1003163.ref004]\] as well as decreased renal excretion in chronic kidney disease (CKD) \[[@pmed.1003163.ref005]\] may also contribute to AGE accumulation. Skin autofluorescence (SAF) measurement has been developed as a noninvasive marker of AGE accumulation in the skin and has been validated using skin biopsy samples \[[@pmed.1003163.ref006]\]. Measurement of SAF can be carried out quickly and easily using portable equipment and may therefore be useful as a noninvasive measure to risk-stratify persons with CKD.

CKD is associated with a marked increase in cardiovascular events (CVEs), but risk assessment tools developed in general population studies tend to underestimate this risk \[[@pmed.1003163.ref007]\], in part because of the importance of nontraditional risk factors. AGE accumulation may be one such risk factor that was suggested by a landmark paper reporting that higher SAF was a strong and independent risk factor for cardiovascular and all-cause mortality (ACM) in persons on haemodialysis \[[@pmed.1003163.ref006]\]. We have previously reported that in persons with earlier stage CKD, higher SAF was associated with multiple risk factors for CVD in a cross-sectional analysis \[[@pmed.1003163.ref008]\] and was a risk factor for increased ACM in univariable but not fully adjusted multivariable models \[[@pmed.1003163.ref009]\]. After a longer observation period in the same cohort, we sought to investigate whether SAF is an independent risk factor for CVEs and ACM persons with CKD stage 3, cared for in primary care.

Methods {#sec008}
=======

The Renal Risk in Derby (RRID) study is a prospective cohort study of persons with CKD stage 3 recruited from primary care across Derbyshire. A detailed description of methods has been published previously \[[@pmed.1003163.ref008],[@pmed.1003163.ref010]\]. The study was conducted according to a prospective protocol and is reported in keeping with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE Checklist](#pmed.1003163.s008){ref-type="supplementary-material"}). Please see [S1 Protocol](#pmed.1003163.s009){ref-type="supplementary-material"} for the latest version of the study protocol.

Participants {#sec009}
------------

Participants were individually recruited from 32 primary care practices across Derbyshire, United Kingdom between 2008 and 2010. Participating practices were asked to invite persons over 18 years of age with CKD stage 3 from CKD registers. Eligible persons were selected using estimated glomerular filtration rate (eGFR) values calculated using the 4-variable modification of diet in renal disease (MDRD) equation modified for use with isotope dilution mass spectrometry (IDMS)-standardised creatinine measurement. Two eGFR readings more than 90 days apart in the range 30 to 59 mL/min/1.73 m^2^ were required to be eligible. Those with a previous renal or other solid organ transplant, with an expected life-expectancy of less than 1 year, or who were unable to attend the baseline visit in person were excluded. A total of 8,280 persons were invited to take part in the study by post; 1,822 persons attended for baseline visits, of whom 1,741 were suitable for recruitment. Baseline SAF measurements were obtained in 1,707 participants, and these are included in the analysis ([Fig 1](#pmed.1003163.g001){ref-type="fig"}). Participants gave written informed consent prior to the baseline assessment. The study was approved by Nottingham Research Ethics Committee 1 (reference number 08/H0403/16) and is included in the National Institute for Health Research (NIHR) clinical research portfolio (NIHR Study ID 6632). The study follows the principles of Good Clinical Practice and the Declaration of Helsinki.

![Flow chart showing the numbers of participants involved at each stage of the study.\
CKD. chronic kidney disease; KDIGO, kidney disease improving global outcomes; SAF, skin autofluorescence.](pmed.1003163.g001){#pmed.1003163.g001}

Data collection {#sec010}
---------------

Study visits took place at the participants' primary care practice at baseline, 1, and 5 years. Prior to each visit, participants completed a background questionnaire covering demographics, medical history, smoking history, and medication history (see [S1 Questionnaire](#pmed.1003163.s010){ref-type="supplementary-material"} for the data questionnaire). Responses were reviewed during the study visit and clarified as needed. Past medical history of CVD was defined as participant-reported previous myocardial infarction, stroke, transient ischaemic attack (TIA), amputation or revascularisation for peripheral vascular disease, and abdominal aortic aneurysm. Participants provided three consecutive early morning urine samples, stored in a refrigerator prior to the study visit. Urine samples were analysed for albumin to creatinine ratio. Blood samples for biochemistry and haematology were taken from each participant. Participants were asked to avoid eating meat for 12 hours prior to their study visit to avoid confounding their serum creatinine results.

At each study visit, height and weight were measured. Three blood pressure measurements that differed by less than 10% were obtained after at least 5 minutes rest using an automatic oscillometric device (UA-767 Plus 30, A&D Medical). The average of three readings was used for analysis.

Laboratory methods {#sec011}
------------------

Blood and urine samples were analysed at a single clinical laboratory at the Royal Derby Hospital. Creatinine was measured using the Jaffe reaction and was standardised to IDMS methods. eGFR was calculated using the MDRD equation \[[@pmed.1003163.ref011]\] at the time of recruitment, but for analysis, this was changed to the more accurate chronic kidney disease epidemiology (CKD-EPI) equation \[[@pmed.1003163.ref012]\], published after recruitment commenced. Additionally, serum was analysed for standard electrolytes and bone mineral profile. Urinary albumin was measured using an immunoturbidimetric assay ('Tina-quant', Roche Diagnostics, Mannheim, Germany) on a Roche Modular system. Urine albumin to creatinine ratio (UACR) was measured on three urine samples from each participant, and a mean value was used for analysis. Serum high-sensitivity C reactive protein (CRP) (hsCRP^™^, Roche Diagnostics, Newhaven, UK) was measured using a Roche Modular P Analyser (Roche Diagnostics) at The Binding Site Group laboratories, Birmingham, UK.

SAF {#sec012}
---

SAF was measured using an AGE reader (DiagnOptics Technologies BV, Groningen, The Netherlands). The AGE reader provides a noninvasive measure of skin AGE levels that has been validated using data from skin biopsies. A light source emitting light at a wavelength of 320 to 400 nm excites fluorescent moieties in compounds in the skin to produce fluorescence at wavelength 420 to 600 nm (peak 440 nm). The output represents the ratio between autofluorescence in the range 420 to 600 nm and excitation light in the range 320 to 400 nm and is reported in arbitrary units (AU). The AGE reader is not able to obtain valid SAF readings when the skin reflectivity is lower than 6%. Persons with dark skin colour (Fitzpatrick skin colour type V--VI) were therefore excluded from this aspect of the study (*n* = 17). Technical failure prevented SAF readings in a further 17 participants. We have previously reported that SAF readings have good reproducibility and repeatability (coefficient of variation of 7%--8%) \[[@pmed.1003163.ref008]\]. Three SAF measurements were taken from the ventral (anterior) surface of the forearm of each participant, avoiding any tattoos or heavily pigmented areas of skin, and the average was used for analysis.

Outcomes {#sec013}
--------

The outcomes of interest for this analysis were fatal and nonfatal CVEs and ACM. Data on all deaths and hospital admissions from date of recruitment to 31 December 2015 were obtained from NHS Digital under a data sharing agreement. NHS Digital holds data on all deaths (from death certificates) and coding data on all hospital admissions in England and Wales. Three investigators (AS, RJF, and MWT) independently classified cause of death as cardiovascular or noncardiovascular. Differences were resolved by discussion. CVEs were defined as any cardiovascular death or hospitalisation that included myocardial infarction, stroke, TIA, cardiac failure, revascularisation, or peripheral vascular disease identified from ICD-10 codes in any of the diagnoses.

Statistical methods {#sec014}
-------------------

Data are presented as mean ± SD or median (interquartile range) depending on distribution. Normally distributed continuous variables were compared across tertiles using ANOVA. Nonparametrically distributed variables were compared using the Kruskal--Wallis test. Categorical variables were compared using chi squared tests. Missing data were omitted from analyses.

We constructed multilevel mixed‐effects models using the mixed command in Stata 15 to investigate factors associated with SAF as a repeated measure at baseline, Year 1, and Year 5. Cox proportional hazards models were constructed to investigate variables associated with time to death from any cause or time to hospitalisation with a CVE or cardiovascular death. All variables that evidenced a significant univariable association (*p* \< 0.05) with the outcome of interest were subsequently entered into multivariable models. Model 1 included demographic and past medical history variables; Model 2 added blood pressure, body mass index (BMI), eGFR, and UACR; Model 3 added all remaining laboratory variables including high-sensitivity C reactive protein (hsCRP). Hazard ratios for continuous variables are expressed per SD change. To facilitate this, continuous variables that were not normally distributed (UACR and hsCRP) were logarithmically transformed prior to inclusion in Cox proportional hazards models.

Analyses were conducted using SPSS version 24 (IBM corporation, NY, USA) and Stata 15 (StataCorp LLC, Texas, USA). *p* \< 0.05 was regarded as statistically significant.

Results {#sec015}
=======

Baseline characteristics {#sec016}
------------------------

Baseline SAF readings were obtained in 1,707 persons and are included in this analysis (98% of a total of 1,741 in the RRID cohort). The mean age of those included was 72.9 ± 9.0 years, 1,036 (60.7%) were female, 1,681 (98.5%) were of white ethnicity, mean eGFR was 53.5 ± 11.9 mL/min/1.73 m^2^. Baseline characteristics (including the number of participants with complete data) are presented in [Table 1](#pmed.1003163.t001){ref-type="table"} by tertile of SAF. Participants in the highest tertile of SAF were more likely to be male, either a current or previous smoker, have type 1 or 2 diabetes, and have a past history of CVD. Additionally, higher age, systolic blood pressure (SBP), UACR, serum uric acid, and hsCRP were associated with a higher tertile of baseline SAF. Lower diastolic blood pressure (DBP), eGFR, haemoglobin, serum albumin, and total cholesterol were associated with higher tertile of baseline SAF.

10.1371/journal.pmed.1003163.t001

###### Baseline characteristics by tertile of SAF.

![](pmed.1003163.t001){#pmed.1003163.t001g}

  Variable                              Number[^a^](#t001fn003){ref-type="table-fn"}   Lowest Tertile (*n* = 560)   Middle Tertile (*n* = 575)   Highest Tertile (*n* = 572)   *P* value
  ------------------------------------- ---------------------------------------------- ---------------------------- ---------------------------- ----------------------------- -----------
  **Baseline SAF (AU)**                 1,707                                          2.1 ± 0.2                    2.7 ± 0.1                    3.4 ± 0.4                     \<0.001
  **Baseline age (years)**              1,707                                          70.7 ± 9.9                   73.0 ± 8.6                   74.9 ± 8.1                    \<0.001
  **Female sex**                        1,707                                          360 (64.3)                   359 (62.4)                   317 (55.4)                    0.005
  **Diabetes**                          1,707                                          50 (8.9)                     82 (14.3)                    152 (26.6)                    \<0.001
  **Previous CVD**                      1,707                                          88 (15.7)                    127 (22.1)                   164 (28.7)                    \<0.001
  **Smoking status**                                                                                                                                                           
  Current                               1,707                                          18 (3.2)                     18 (3.1)                     43 (7.5)                      \<0.001
  Previous                              1,707                                          242 (43.2)                   283 (49.2)                   327 (57.2)                    \<0.001
  **BMI (kg/m**^**2**^**)**             1,706                                          28.7 ± 4.9                   29.3 ± 5.3                   29.1 ± 5.2                    0.2
  **Systolic BP (mmHg)**                1,707                                          133 ± 18                     133 ± 18                     136 ± 19                      0.006
  **Diastolic BP (mmHg)**               1,707                                          74 ± 11                      73 ± 11                      71 ± 11                       \<0.001
  **eGFR (mL/min/1.73 m**^**2**^**)**   1,707                                          57.1 ± 11.2                  53.6 ± 11.0                  49.9 ± 12.2                   \<0.001
  **UACR (mg/mmol)**                    1,704                                          0.2 (0.0--0.9)               0.3 (0.0--1.3)               0.6 (0.0--3.0)                \<0.001
  **Albumin (g/l)**                     1,704                                          41.1 ± 2.9                   41.0 ± 3.4                   40.2 ± 3.1                    \<0.001
  **Phosphate (mmol/l)**                1,676                                          1.11 ± 0.17                  1.11 ± 0.18                  1.11 ± 0.18                   0.90
  **Calcium (mmol/l)**                  1,696                                          2.38 ± 0.10                  2.37 ± 0.10                  2.38 ± 0.10                   0.4
  **Bicarbonate (mmol/l)**              1,688                                          25.6 ± 2.5                   25.6 ± 2.7                   25.3 ± 2.9                    0.06
  **Urate (umol/l)**                    1,697                                          374 ± 88                     390 ± 96                     387 ± 88                      0.005
  **Total Cholesterol (mmol/l)**        1,698                                          4.9 ± 1.2                    4.8 ± 1.2                    4.6 ± 1.1                     \<0.001
  **HDL Cholesterol (mmol/L)**          1,698                                          1.47 ± 0.43                  1.47 ± 0.45                  1.42 ± 0.42                   0.08
  **Haemoglobin (g/dl)**                1,702                                          13.5 ± 1.3                   13.3 ± 1.4                   12.9 ± 1.5                    \<0.001
  **hsCRP (mg/L)**                      1,706                                          2.06 (1.04--4.02)            2.10 (1.09--4.50)            2.56 (1.30--5.26)             0.001

Data are presented as mean ± SD, number (percentage), or median (interquartile range).

*P* values for trend across tertiles by ANOVA, Chi squared test, or Kruskal--Wallis test.

^a^Number of complete data for each variable.

**Abbreviations**: AU, arbitrary units; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio

Change in SAF over time {#sec017}
-----------------------

Among 948 participants who had SAF measured at baseline and Year 5, no change in mean SAF was observed over time (baseline: 2.6 ± 0.6 AU; Year 1: 2.5 ± 0.5 AU, Year 5: 2.7 ± 0.6 AU; *p* = 0.1). Multilevel mixed-effects models showed that greater age, male sex, diabetes, previous CVD, current or previous smoking, lower eGFR, lower serum albumin, and lower haemoglobin were independently associated with higher SAF in repeated measures over the follow-up period ([Table 2](#pmed.1003163.t002){ref-type="table"}).

10.1371/journal.pmed.1003163.t002

###### Multilevel mixed-effects models for associations with SAF as a repeated measure at baseline, Year 1, and Year 5.

![](pmed.1003163.t002){#pmed.1003163.t002g}

  Variable                Univariable analysis     Multivariable analysis (*n* = 1,668)                            
  ----------------------- ------------------------ -------------------------------------- ------------------------ ---------
  **Age**                 0.01 (0.01--0.02)        \<0.001                                0.01 (0.00--0.01)        \<0.001
  **Male sex**            0.16 (0.10--0.21)        \<0.001                                0.11 (0.05 to −0.16)     \<0.001
  **Diabetes**            0.34 (0.28--0.41)        \<0.001                                0.23 (0.16--0.30)        \<0.001
  **Previous CVD**        0.22 (0.16--0.29)        \<0.001                                0.11 (0.05--0.17)        \<0.001
  **Previous smoker**     0.15 (0.09--0.20)        \<0.001                                0.10 (0.05--0.15)        \<0.001
  **Current smoker**      0.28 (0.16--0.40)        \<0.001                                0.41 (0.29--0.52)        \<0.001
  **eGFR**                −001 (−0.02 to −0.01)    \<0.001                                −0.01 (−0.01 to −0.00)   \<0.001
  **UACR**                0.00 (0.00--0.00)        0.02                                   −0.00 (−0.00 to 0.00)    0.84
  **Total cholesterol**   −0.09 (−0.11 to −0.07)   \<0.001                                −0.02 (−0.04 to −0.00)   0.08
  **Albumin**             −0.02 (−0.03 to −0.02)   \<0.001                                −0.01 (−0.02 to −0.00)   0.02
  **Bicarbonate**         −0.02 (−0.03 to −0.01)   \<0.001                                −0.01 (−0.02 to 0.00)    0.18
  **Haemoglobin**         −0.08 (−0.10 to −0.07)   \<0.001                                −0.06 (−0.08 to −0.04)   \<0.001
  **hsCRP**               0.00 (0.00--0.01)        \<0.001                                0.00 (−0.00 to 0.00)     0.09

**Abbreviations**: CVD, cardiovascular disease, eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio

CVEs {#sec018}
----

We observed 590 CVEs during 5.1 ± 2.2 years of observation, of which 105 were fatal. Kaplan--Meier analysis showed a progressive increase in CVEs across tertiles of baseline SAF ([Fig 2](#pmed.1003163.g002){ref-type="fig"}). Additionally, multivariable Cox proportional hazards analysis identified SAF at baseline as an independent risk factor for time to first CVE (HR 1.12 per SD increase, 95% CI 1.03--1.22, *p* = 0.01) together with age, male sex, history of previous CVD, higher UACR, lower DBP, lower serum albumin, and higher hsCRP ([Table 3](#pmed.1003163.t003){ref-type="table"}). In subgroup analyses, baseline SAF remained independently associated with nonfatal CVEs ([S1 Table](#pmed.1003163.s001){ref-type="supplementary-material"}) but an association with fatal CVEs in the univariable analysis and initial multivariable analysis (Model 1) was not maintained after full multivariable analysis ([S2 Table](#pmed.1003163.s002){ref-type="supplementary-material"}). In a further subgroup analysis of participants with no events during the first year, change in SAF over 1 year was independently associated with CVEs (HR 1.11 per SD increase, 95% CI 1.00--1.22; *p* = 0.04) though the association with baseline SAF was attenuated (HR 1.12 per SD increase, 95% CI 1.00--1.27; *p* = 0.06; [S3 Table](#pmed.1003163.s003){ref-type="supplementary-material"}).

![Kaplan--Meier plot showing CVE free survival by tertiles of SAF (dotted line, lowest tertile; dashed line, middle tertile; solid line, highest tertile; log-rank test: chi-square 41.4; *p* \< 0.001).\
CVE, cardiovascular event; SAF, skin autofluorescence.](pmed.1003163.g002){#pmed.1003163.g002}

10.1371/journal.pmed.1003163.t003

###### Cox proportional hazards model showing variables associated with time to first CVE.

![](pmed.1003163.t003){#pmed.1003163.t003g}

  Variable                Univariable         Model 1 (*n* = 1,707)   Model 2 (*n* = 1,703)   Model 3 (*n* = 1,675)                                                     
  ----------------------- ------------------- ----------------------- ----------------------- ----------------------- ------------------- --------- ------------------- ---------
  **SAF**                 1.37 (1.27--1.48)   \<0.001                 1.20 (1.10--1.30)       \<0.001                 1.15 (1.06--1.25)   0.001     1.12 (1.03--1.22)   0.01
  **Age**                 1.54 (1.41--1.69)   \<0.001                 1.39 (1.26--1.53)       \<0.001                 1.31 (1.18--1.46)   \<0.001   1.31 (1.17--1.45)   \<0.001
  **Male sex**            1.79 (1.52--2.11)   \<0.001                 1.47 (1.24--1.74)       \<0.001                 1.45 (1.22--1.73)   \<0.001   1.51 (1.23--1.86)   \<0.001
  **Diabetes**            1.33 (1.08--1.62)   0.006                   1.09 (0.89--1.35)       0.4                     0.94 (0.76--1.17)   0.6       0.95 (0.76--1.20)   0.6
  **Previous CVD**        2.51 (2.12--2.97)   \<0.001                 1.94 (1.63--2.31)       \<0.001                 1.90 (1.59--2.27)   \<0.001   1.94 (1.62--2.33)   \<0.001
  **Hypertension**        1.76 (1.31--2.36)   \<0.001                 1.28 (0.95--1.73)       0.1                     1.14 (0.84--1.56)   0.4       1.23 (0.90--1.69)   0.2
  **Ever smoked**         1.44 (1.22--1.69)   \<0.001                 1.14 (0.96--1.35)       0.2                     1.10 (0.92--1.31)   0.3       1.08 (0.91--1.29)   0.4
  **Systolic BP**         1.06 (0.98--1.15)   0.2                                                                     1.01 (0.91--1.11)   0.9       1.01 (0.92--1.12)   0.8
  **Diastolic BP**        0.79 (0.73--0.86)   \<0.001                                                                 0.89 (0.80--0.98)   0.02      0.89 (0.80--0.99)   0.03
  **BMI**                 1.03 (0.95--1.12)   0.5                                                                     1.12 (1.02--1.22)   0.01      1.08 (0.99--1.19)   0.09
  **eGFR**                0.69 (0.63--0.75)   \<0.001                                                                 0.88 (0.80--0.97)   0.009     0.93 (0.84--1.04)   0.2
  **UACR (log)**          1.31 (1.20--1.43)   \<0.001                                                                 1.15 (1.05--1.26)   0.002     1.12 (1.02--1.22)   0.02
  **Albumin**             0.80 (0.74--0.86)   \<0.001                                                                                               0.89 (0.81--0.96)   0.005
  **Uric acid**           1.23 (1.14--1.34)   \<0.001                                                                                               1.02 (0.92--1.12)   0.7
  **Total cholesterol**   0.80 (0.73--0.87)   \<0.001                                                                                               1.05 (0.95--1.15)   0.3
  **HDL cholesterol**     0.79 (0.72--0.87)   \<0.001                                                                                               0.91 (0.82--1.01)   0.07
  **Haemoglobin**         0.84 (0.77--0.91)   \<0.001                                                                                               0.94 (0.86--1.03)   0.2
  **hsCRP (log)**         1.25 (1.15--1.35)   \<0.001                 \-                                                                            1.11 (1.02--1.21)   0.02

Hazard ratios for continuous variables are expressed per SD change.

**Abbreviations**: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; CVE, cardiovascular event; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HR, hazard ratio; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio

ACM {#sec019}
---

We observed 319 deaths (ACM) during 6.0 ± 1.5 years of observation. Kaplan--Meier analysis showed a progressive increase in risk of ACM across tertiles of baseline SAF ([Fig 3](#pmed.1003163.g003){ref-type="fig"}). Additionally, multivariable analysis identified SAF at baseline as an independent risk factor for ACM (HR 1.16 per SD increase, 95% CI 1.03--1.30, *p* = 0.01) together with age, male sex, history of previous CVD, lower eGFR, and higher hsCRP ([Table 4](#pmed.1003163.t004){ref-type="table"}). In subgroup analyses, baseline SAF remained independently associated with noncardiovascular deaths ([S4 Table](#pmed.1003163.s004){ref-type="supplementary-material"}), but an association with cardiovascular deaths in the univariable analysis and initial multivariable analysis (Model 1) was not maintained after full multivariable analysis ([S2 Table](#pmed.1003163.s002){ref-type="supplementary-material"}). In a further subgroup analysis of participants who survived beyond the first year, change in SAF over 1 year was independently associated with ACM (HR 1.24 per SD increase, 95% CI 1.09--1.41, *p* = 0.001) in addition to baseline SAF (HR 1.25 per SD increase, 95% CI 1.07--1.45; *p* = 0.005; [S5 Table](#pmed.1003163.s005){ref-type="supplementary-material"}).

![Kaplan--Meier plot showing survival by tertiles of SAF (dotted line, lowest tertile; dashed line, middle tertile; solid line, highest tertile; log-rank test: chi-square 42.5; *p* \< 0.001).\
SAF, skin autofluorescence.](pmed.1003163.g003){#pmed.1003163.g003}
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###### Cox proportional hazards model showing variables associated with time to death from any cause.

![](pmed.1003163.t004){#pmed.1003163.t004g}

  Variable                Univariable         Model 1 (*n* = 1,707)   Model 2 (*n* = 1,703)   Model 3 (*n* = 1,675)                                                     
  ----------------------- ------------------- ----------------------- ----------------------- ----------------------- ------------------- --------- ------------------- ---------
  **SAF**                 1.51 (1.37--1.67)   \<0.001                 1.26 (1.13--1.40)       \<0.001                 1.19 (1.06--1.33)   0.003     1.16 (1.03--1.30)   0.01
  **Age**                 2.46 (2.14--2.83)   \<0.001                 2.26 (1.96--2.61)       \<0.001                 1.93 (1.65--2.25)   \<0.001   1.90 (1.62--2.23)   \<0.001
  **Male sex**            2.02 (1.62--2.51)   \<0.001                 1.51 (1.20--1.90)       0.001                   1.35 (1.07--1.72)   0.01      1.37 (1.03--1.81)   0.03
  **Diabetes**            1.45 (1.11--1.89)   0.007                   1.18 (0.90--1.55)       0.2                     1.09 (0.82--1.45)   0.6       1.08 (0.80--1.46)   0.6
  **Previous CVD**        2.38 (1.90--2.98)   \<0.001                 1.66 (1.32--2.10)       \<0.001                 1.64 (1.30--2.08)   \<0.001   1.62 (1.27--2.06)   \<0.001
  **Hypertension**        1.66 (1.11--2.47)   0.014                   1.00 (0.67--1.51)       1.0                     0.87 (0.57--1.33)   0.5       0.94 (0.61--1.46)   0.8
  **Ever smoked**         1.71 (1.36--2.16)   \<0.001                 1.33 (1.05--1.70)       0.02                    1.27 (0.99--1.62)   0.06      1.21 (0.94--1.54)   0.1
  **Systolic BP**         1.12 (1.00--1.25)   0.05                                                                    1.01 (0.89--1.15)   0.9       1.03 (0.90--1.18)   0.7
  **Diastolic BP**        0.75 (0.67--0.84)   \<0.001                                                                 0.93 (0.81--1.07)   0.3       0.93 (0.80--1.07)   0.3
  **BMI**                 0.85 (0.75--0.95)   0.005                                                                   0.94 (0.83--1.07)   0.3       0.91 (0.79--1.04)   0.2
  **eGFR**                0.52 (0.46--0.58)   \<0.001                                                                 0.73 (0.64--0.84)   \<0.001   0.77 (0.66--0.89)   0.001
  **UACR (log)**          1.47 (1.30--1.66)   \<0.001                                                                 1.19 (1.05--1.35)   0.007     1.12 (0.98--1.28)   0.09
  **Albumin**             0.78 (0.71--0.85)   \<0.001                                                                                               0.92 (0.81--1.04)   0.2
  **Uric acid**           1.30 (1.17--1.45)   \<0.001                                                                                               1.02 (0.90--1.16)   0.7
  **Total cholesterol**   0.71 (0.63--0.80)   \<0.001                                                                                               0.94 (0.82--1.09)   0.4
  **HDL cholesterol**     0.81 (0.71--0.91)   0.001                                                                                                 0.98 (0.86--1.13)   0.8
  **Haemoglobin**         0.76 (0.68--0.85)   \<0.001                                                                                               0.98 (0.87--1.11)   0.8
  **hsCRP (log)**         1.41 (1.27--1.56)   \<0.001                                                                                               1.25 (1.12--1.40)   \<0.001

Hazard ratios for continuous variables are expressed per SD change.

**Abbreviations**: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HR, hazard ratio; hsCRP, high-sensitivity C reactive protein; SAF, skin autofluorescence; UACR, urine albumin to creatinine ratio

Sensitivity analysis {#sec020}
--------------------

Sensitivity analyses were undertaken after excluding participants with diabetes to test whether associations with SAF could be attributable to higher SAF values in persons with diabetes. Among 1,423 participants without diabetes, higher SAF remained independently associated with time to first CVE (HR 1.13 per SD increase; 95% CI 1.02--1.25; *p* = 0.02; [S6 Table](#pmed.1003163.s006){ref-type="supplementary-material"}), but the association with ACM was no longer statistically significant (HR 1.08 per SD increase, 95% CI 0.95--1.24; *p* = 0.3) in fully adjusted models ([S7 Table](#pmed.1003163.s007){ref-type="supplementary-material"}).

Discussion {#sec021}
==========

We have identified higher SAF as an independent risk factor for CVEs and ACM in a cohort of persons with predominantly early CKD stage 3. Additionally, an increase in SAF over 1 year was an independent predictor of CVEs and ACM. Our observations extend the findings of previous studies that identified higher SAF as an independent risk factor for cardiovascular mortality and ACM in persons receiving haemodialysis \[[@pmed.1003163.ref006]\] by showing that this association is also present at a much earlier stage of CKD. Sensitivity analyses confirmed that the association with CVEs persisted when persons with diabetes were excluded, though the association with ACM was no longer significant.

Several individual studies and a meta-analysis have confirmed that higher SAF is a strong and independent predictor of cardiovascular mortality and ACM in persons receiving haemodialysis (HD). The first comprehensive study to report this association found that each 1 AU increase in baseline SAF was independently associated with an odds ratio (OR) of 3.9 (95% CI 1.9--8.1) for ACM and an OR of 6.8 (95% CI 2.6--17.5) for cardiovascular mortality in a cohort of 109 persons on HD after 3 years of follow-up \[[@pmed.1003163.ref006]\]. A meta-analysis that included 10 studies of persons with diabetes (*n* = 2), peripheral arterial disease (*n* = 1), and CKD (*n* = 7), reported that higher SAF was associated with an increased risk of cardiovascular mortality and ACM. In a subgroup analysis that included only studies of HD patients, higher SAF was similarly associated with higher risk of cardiovascular mortality (HR 1.97; 95% CI 1.11--3.49) and ACM (HR 2.37; 95% CI 1.72--3.26) \[[@pmed.1003163.ref013]\]. Additionally, in one study, an increase in SAF over 1 year was independently associated with higher subsequent mortality on HD \[[@pmed.1003163.ref014]\]. Similar observations have been reported in persons performing peritoneal dialysis (PD), though a relatively small number of participants precluded multivariable analysis \[[@pmed.1003163.ref015],[@pmed.1003163.ref016]\]. In a mixed study population of persons with predialysis CKD stage 5 or receiving HD and PD, higher SAF predicted ACM in a multivariable analysis that included traditional Framingham risk factors but was no longer significant after the addition of previous CVD, C reactive protein (CRP), and serum albumin \[[@pmed.1003163.ref017]\]. In persons with earlier stages of CKD, higher SAF has been associated with several aspects of CVD including coronary artery calcification \[[@pmed.1003163.ref018]\], subclinical atherosclerosis \[[@pmed.1003163.ref019]\], and arterial stiffness \[[@pmed.1003163.ref008]\]. Similarly, previous analyses from the RRID cohort reported independent associations between higher SAF and multiple cardiovascular risk factors including older age, male sex, diabetes, past history of CVD, smoking status, lower eGFR, higher urine protein to creatinine ratio, lower haemoglobin, and lower socioeconomic status \[[@pmed.1003163.ref008]\]. An analysis of deaths after a mean of 3.6 years of observation found that higher SAF was a predictor of ACM in univariable as well as age and sex adjusted models but not in a fully adjusted model \[[@pmed.1003163.ref009]\]. With the benefit of a longer observation period resulting in a greater number of outcome events, we have confirmed that higher baseline SAF and increase in SAF over 1 year are independent predictors of CVEs and ACM in early stage CKD after adjustment for traditional risk factors and, importantly, also CRP. One study has reported that higher SAF predicted incident diabetes, CVEs, and ACM in a large cohort enrolled from the general population \[[@pmed.1003163.ref020]\].

Several mechanisms may account for the association between higher SAF and CVEs as well as mortality. AGEs form cross-links between collagen and elastin molecules in arterial walls resulting in arterial stiffness that has been strongly implicated in the pathogenesis of CVD related to CKD \[[@pmed.1003163.ref001]\]. Additionally, AGEs bind to a specific receptor (receptor for AGE \[RAGE\]) and provoke endothelial dysfunction \[[@pmed.1003163.ref021]\] as well as inflammation \[[@pmed.1003163.ref022]\] that likely contribute to the pathogenesis of atherosclerosis. Furthermore, in murine models, atherosclerosis was significantly ameliorated by blockade of RAGE or administration of soluble RAGE \[[@pmed.1003163.ref023]\], suggesting reduced activation of RAGE may prevent atherosclerosis and reduce cardiovascular risk.

Few studies have described longitudinal changes in SAF over time. We found no significant changes in mean SAF over 5 years, but as higher SAF associates with mortality, those with higher baseline levels or a greater increase over time would have been less likely to survive to year 5 follow-up. In multilevel mixed-effects models, we identified multiple baseline variables that were independently associated with higher SAF in repeated measures over the follow-up period including greater age, male sex, diabetes, current or past history of smoking, previous CVD, lower eGFR, lower serum albumin, and lower haemoglobin. These findings are consistent with previous cross-sectional studies that have reported associations between higher SAF and lower GFR as well as other cardiovascular risk factors \[[@pmed.1003163.ref008]\]. Other factors, such as dietary intake and cooking methods, have been associated with changes in AGE levels but were not captured in this population.

SAF is of particular interest as a risk marker, because it is potentially modifiable. A cross-sectional analysis showed lower SAF levels in renal transplant recipients compared to those on either PD or HD, implying that SAF decreases with improved GFR after transplantation \[[@pmed.1003163.ref024]\]. This was confirmed by observation of a decrease in SAF levels in a small number of renal transplant recipients, compared with SAF values recorded while they were on dialysis \[[@pmed.1003163.ref024]\]. AGEs may also enter the body from exogenous sources, including smoking and diet, particularly foods cooked at high temperatures. Dietary changes may therefore also reduce tissue AGE accumulation and SAF measurements. This notion is supported by a cross-sectional analysis of the impact of diet on SAF in persons on HD which reported lower SAF in 27 of 332 participants who followed a vegetarian diet, predicted to be low in AGE content \[[@pmed.1003163.ref025]\]. Furthermore, small randomised studies in persons on HD (*n* = 18) \[[@pmed.1003163.ref026]\] and PD (*n* = 20) \[[@pmed.1003163.ref027]\] have reported a reduction in serum AGE levels in response to a low AGE diet, though SAF was not assessed. The hypothesis that dietary AGE restriction is effective to reduce CVEs and improve survival in persons with CKD requires testing in prospective randomised controlled trials.

Sensitivity analyses showed that the association between SAF and CVEs remained present when persons with diabetes were excluded, confirming that elevated SAF was not simply a surrogate for diabetes. Additionally in the multivariable analyses, SAF was an independent predictor of CVEs and ACM but diabetes was not (Tables [3](#pmed.1003163.t003){ref-type="table"} and [4](#pmed.1003163.t004){ref-type="table"}).

Limitations of this study include a predominantly white and elderly study population. Additionally, the AGE reader is limited in its applicability to persons of African and African-Caribbean ethnicity because of reduced levels of reflected light from darker skin. Our findings may therefore not be applicable to more ethnically diverse or younger populations. Additionally, 1,822 out of 8,280 persons who were invited agreed to participate in the study, potentially resulting in some selection bias. Nevertheless, the baseline data indicate that our study population was representative of patients with CKD followed up in primary care in England \[[@pmed.1003163.ref028]\]. We relied on ICD-10 codes to identify hospital admissions with CVE, and there may therefore have been some misclassification. Nevertheless, coding practice is well-established and rigorous in the NHS, and similar coding data have been used in other large cohort studies including the UK Biobank \[[@pmed.1003163.ref029]\]. At very least, each code represents a hospital admission. Office blood pressure was recorded, but ambulatory blood pressure was not assessed. We were therefore unable to assess the impact of masked hypertension or nocturnal dipping on outcomes. The observed association of lower cholesterol with CVEs and ACM may have resulted from reverse causality due to more persons with CVD receiving lipid lowering therapy. Unfortunately, data on lipid lowering therapy were not available for inclusion in the analysis. Because this was an observational study, the observed associations should not be interpreted as indicating a causal link between SAF and CVEs or ACM. Prospective trials of interventions that reduce SAF will be required to explore this. Finally, the subgroup analyses should be interpreted with consideration of the fact that in each case a lower number of events resulted in reduced statistical power.

Conclusions {#sec022}
===========

This analysis showed that higher SAF was independently associated with an increased risk of CVEs and ACM in the largest cohort of persons with CKD stage 3 studied to date. An additional novel finding was that change in SAF over 1 year was associated with an increased risk of CVEs and ACM. These findings support the hypothesis that interventions aimed at reducing AGE levels would be potentially beneficial in improving cardiovascular outcomes and survival in persons with CKD, but this should now be tested in prospective randomised trials.

Supporting information {#sec023}
======================
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Dear Dr. Taal,

Thank you very much for submitting your manuscript \"Skin autofluorescence as a risk factor for cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3\" (PMEDICINE-D-20-00405R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:
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In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.
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Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.
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Requests from the editors:

Title- Please revise your title according to PLOS Medicine\'s style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. \"Effect of\" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon).

Abstract- please provide details of where this study was carried out, dates of patient recruitment/ data collection as appropriate and brief patient demographics

Abstract methods and findings- the last sentence should be a limitation of your study design

The Data Availability Statement (DAS) requires revision. For each data source used in your study:

a\) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number).

b\) If the data are owned by a third party but freely available upon request, please note this and state the owner of the data set and contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data.

c\) If the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author).

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

STROBE checklist-please do not use page numbers as these are likely to change. Please use paragraphs and sections instead

Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\"

Questionnaires- please provide a copy of all questionnaires used in the study, if previously published please provide a citation. The same goes for the equations mentioned on Pages 6 and 7

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section. a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript. b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place. c) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Please replace Caucasian with white

Please include all financial information into the financial disclosure section within article meta-data instead of the acknowledgements

Comments from the reviewers:

Reviewer \#1: I confine my remarks to statistical aspects of this paper. The general approach is mostly fine, but I do have some issues to resolve before I can recommend publication.

Line 36 (and 162) \"Determinants\" is too causal. I\'m not sure what word to suggest here. Perhaps the editors have a suggestion. But, this is an observational study , so, we only know that these were associated with CVE and ACM.

Line 38 What is after the +- sign? Is that an SD? A 95% CI? or something else?

Line 141 - not a stats comment, but maybe say whether it was the posterior or anterior portion of the forearm? (I only mention this because you discuss skin color and the anterior portion is differently colored than the posterior)

Line 158 - Please specify that it is tertiles of SAF. But why compare across tertiles using ANOVA? it would be better to leave SAF continuous and use regression. (Tertiles might be useful for a table, but categorizing variables for analysis loses power. In addition, nonlinearities can be investigated with splines.

Line 169-170 Linear regression on change scores is not generally recommended, unless the scores are measured perfectly - I\'m not sure how well SAF measurements work - a better method is a multilevel model.

Line 170-172 Why were variables log transformed? Linear regression makes no assumptions about the distribution of the variables (it makes assumptions about the residuals).

Figures 2 and 3 - I would use \"Years\" rather than \"Days\" just for ease of reading. (People don\'t think \"400 days\" they think \"a year and a quarter\"). I would consider limiting the y axis to 0.5 and up - although this is debatable. It allows finer discrimination but might give the wrong idea to someone who doesn\'t look at the y axis.

Peter Flom

Reviewer \#2: The authors analyze the associations of skin autofluorescence (SAF), a biomarker of tissue accumulation of advanced glycation endproducts, with incidence of cardiovascular events and mortality, in a cohort of 1707 patients affected by stage 3 chronic kidney disease. SAF is a non invasive and quick measurement, which appears to be predictive of adverse health outcomes in particular in diabetic patients. Several studies have evidenced an association of SAF with increased risk for cardiovascular disease and mortality in patients in hemodialysis. However, there are few available data on this association at earlier stages of CKD, who exhibit higher SAF values than the general population. This study thus addresses an important issue, which could help identify specific mechanisms of cardiovascular disease in CKD patients. The methods are sound and the paper is generally well written.

In addition to the analysis of incidence of cardiovascular events and all-cause mortality, the authors should consider adding supplementary analyses regarding cardiovascular and non-cardiovascular mortality. Indeed, it would be informative to differentiate the associations of SAF with fatal versus non fatal cardiovascular events, as well as with mortality from other causes, in order to document the specificity of these associations.

Specific comments:

Title: As \"skin autofluorescence\" is a rather unspecific term, consider adding \"advanced glycation endproducts\" in the title.

Abstract: add the number of participants in the methods.

Statistical methods (page 8, lines 162-168): in the Cox models, SAF was modeled as a continuous variable, thus hypothesizing a linear relationship of SAF with the outcomes. Has this hypothesis been verified ?

Table 1: there is one decimal missing for phosphate in the lowest tertile. A second decimal could also be added for this variable.

Tables 3 and 4: were there any missing data for the covariables ? Please add number of analyzed participants in all analyses.

Discussion (page 21): the authors should also cite the potential selection bias as a limitation of this study, as only 1741 of 8280 invited patients were initially included. This may limit the generalization of the results.

Reviewer \#3: This is an important prospective study in a large cohort of patients at an early stage of Chronic Kidney Disease regarding skin autofluorescence as a risk factor for cardiovascular events and all-cause mortality.

Increased cardiovascular morbidity and mortality in CKD patients is caused by traditional and non-traditional risk factors. The search for new non-traditional CV risk factors, particularly modifiable, which may affect the prognosis in this group of patients, is an important clinical aspect of the study.

My suggestions:

Methods:

1\. What kits were used to analyze urine albumin to creatinine ratio?

2\. As the medication history was collected at each visit please include the information on how many patients were on lipid lowering therapy?

3\. How many patients had malnutrition?

4\. Both total and HDL cholesterol were used in analyses. Why was the LDL cholesterol, which increased concentration is a known CV mortality risk factor, and is used as therapeutic goal, not a part of the analyses?

5\. Line 169 - BMI abbreviation has not been previously expanded

Results:

1\. Line 184 - SBP abbreviation has not been previously expanded

2\. Line 185 - DBP abbreviation has not been previously expanded

Discussion:

1\. The Authors properly identify that \"the association with lower cholesterol may have resulted from reverse causality due to more persons with CVD receiving lipid lowering therapy.\" However, the most commonly used lipid lowering drugs, statins, except for lowering cholesterol concentrations, possess pleiotropic effects, including decreasing RAGE expression. Therefore statin taking, as a potential confounder, should be a part of the analyses.

2\. Please include in limitations that office BP and not ABPM was measured. In CKD patients specific form of hypertension - masked hypertension and non-dipping BP profile, which are known to increase CV risk, are present. The diagnosis is possible only with the use of ABPM.

Acknowledgements:

1\. According to PLOS submission guidelines please \"Do not include funding sources in the Acknowledgments or anywhere else in the manuscript file. Funding information should only be entered in the financial disclosure section of the submission system.\"

Reviewer \#4: This is a well designed prospective study performed by an experienced team in the field. In fact, it is a continuation of an already published work by these authors. It adds on additional information of the role of AGEs on the clinical outcome of the patients with Chronic kidney disease stage 3. There is also some new information in this paper: the finding that over time the accumulation of AGEs in the body rises, with an implication that the risk for development of cardiovascular events or all cause mortality rises too. It also points out the direction of future research in this field, designing prospective interventional clinical studies with an intention to reduce AGEs and consequently the adverse clinical outcomes in the patients. The paper is clearly and critically written. It is a significant contribution to the existing literature. I would like to congratulate the authors for the excellent work and gladly recommend publication.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003163.r003
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Dear Dr. Taal,

Thank you very much for re-submitting your manuscript \"The association of skin autofluorescence, a measure of advanced glycation endproduct accumulation, with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: a prospective cohort study\" (PMEDICINE-D-20-00405R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.
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